Pharma News
12 Oct 2025 to 18 Oct 2025
Oct 18, 2025
Novo Nordisk Names Greg Miley as Head of Corporate Affairs in Response to U.S. Drug Pricing Challenges
Novo Nordisk has appointed Greg Miley, former senior VP of government affairs at AbbVie, as its new head of corporate affairs to enhance its political strategy amid rising drug pricing pressures from the Trump administration. Miley will relocate to Denmark next month, focusing on managing relations with the U.S. government as Novo faces competition from Eli Lilly in the obesity drug market.
Oct 18, 2025
Gilead Sciences Shares Surge Following Patent Victory and Advances in HIV Treatment – Can the Uptrend Persist?
Gilead Sciences (NASDAQ: GILD) stock reached a new 52-week high of $123 on October 17, 2025, driven by a patent settlement extending exclusivity for its HIV drug Biktarvy until 2036 and the FDA approval of its new HIV prevention shot, Yeztugo (lenacapavir). Analysts remain optimistic, with price targets rising amid strong financial performance and growth prospects.
Oct 17, 2025
Novo Nordisk (NYSE:NVO) Offers Affordable Shares, With Patent Protections Ensuring Profitability Through 2032
Novo Nordisk A/S (NASDAQ:NVO) faces market jitters following President Trump's call for a price cut on its weight-loss drug, Ozempic. Despite this, the stock remains attractively priced at a 14 P/E, with core drug patents protected until 2032. The company’s portfolio, including Wegovy, positions it well for long-term growth in diabetes and obesity treatments.
Oct 17, 2025
Understanding Conception and Inventorship in Pharmaceutical Patent Law: Key Takeaways and Recommended Approaches
Pharmaceutical companies must ensure accurate inventorship to protect patents, as misidentification can lead to invalidation and litigation. Key cases like Burroughs Wellcome and Auxilium highlight the importance of specific contributions in patent claims. Companies should conduct inventor audits, maintain robust documentation, and implement trade secret protections to safeguard their innovations and enforce patent rights effectively.
Oct 17, 2025
Remuneration for the Duration of Pharmaceutical Patents - Lexology
China's newly revised Patent Law introduces provisions for extending pharmaceutical patent terms due to delays in drug marketing authorization. Patent holders can request compensation within three months of approval, provided specific conditions are met. The compensation period can be up to five years, with a maximum effective patent term of 14 years post-approval.
Oct 17, 2025
Novo Nordisk's $9.2 billion gamble: Could Ozempic be a treatment for Alzheimer's? - Mint
Novo Nordisk's semaglutide, known as Ozempic or Wegovy, has emerged as a groundbreaking drug, regulating blood sugar, aiding weight loss, and reducing heart attack risk. The GLP-1 agonist has gained significant traction, with Novo Nordisk commanding a 62% market share, up from 60% three years ago, highlighting its success in the pharmaceutical market.
Oct 17, 2025
California's state-operated medication initiative considers broadening its scope to include vaccines, diapers, and GLP-1 medications - Pluribus News
California's CalRx program, aimed at providing low-cost pharmaceuticals, may soon include vaccines, diapers, and popular GLP-1 drugs. Governor Gavin Newsom announced the addition of an $11 insulin pen, highlighting the state's strategy to combat rising drug prices affecting policymakers nationwide.
Oct 17, 2025
Novo Nordisk stock drops 6% following Trump's promise to reduce prices on weight-loss medications - BNN Bloomberg
Novo Nordisk shares dropped 6.4% after U.S. President Donald Trump indicated that prices for the company's weight-loss drugs, including Ozempic, would be reduced under a new policy. Analysts at UBS had anticipated these price cuts. The company's stock fell to a near three-week low, impacting shares of competitors Eli Lilly and Zealand Pharma as well.
Oct 17, 2025
Global Market Projections for Pharmaceutical Contract Manufacturing Through 2030 - Business Wire
The global pharmaceutical contract manufacturing market is projected to grow from USD 209.90 billion in 2025 to USD 311.95 billion by 2030, at a CAGR of 8.2%. Key players include Thermo Fisher Scientific, Lonza, and AbbVie. Growth is driven by demand for biologics and advanced therapies, despite challenges like pricing pressure and regulatory compliance.
Oct 17, 2025
Street View: Praxis achieves unexpected victory in trial, recognizes significant growth opportunities - TradingView
Praxis Precision Medicines announced that its experimental drug, ulixacaltamide, successfully met the primary goals in two late-stage studies for essential tremor. Following this unexpected success, at least nine analysts raised their price targets for PRAX. The company also revealed a $525 million public offering, with expectations that ulixacaltamide could achieve blockbuster status by 2028.
Oct 17, 2025
Novo and Lilly Decline as Trump Promises 'Significantly Reduced' Ozempic Cost - Yahoo Finance
Shares of Novo Nordisk A/S and Eli Lilly & Co. fell after President Trump suggested the price of Ozempic, a diabetes drug by Novo, could drop to $150 monthly from its current $1,000. This potential price cut, amid ongoing negotiations for weight-loss drugs, raised concerns about market impacts, with Novo's shares down 7% and Lilly's 4.3%.
Oct 17, 2025
Is it advisable for seniors to take popular weight loss medications? A physician discusses their effects on muscle health.
A rising interest in weight loss medications, particularly GLP-1 receptor agonists, is noted among older adults, as they can aid in weight loss and reduce health risks. However, caution is advised due to potential muscle loss, especially in seniors. Adequate protein intake and structured exercise are recommended to mitigate these risks, emphasizing the need for medical supervision.
Oct 17, 2025
Vimmy Pharma intends to manufacture a Canadian-made generic version of Ozempic.
Vimy Pharma, co-founded by Dave Suchon, plans to produce a generic version of the weight-loss drug Ozempic, which contains semaglutide, to offer affordable options for Canadians. With exclusivity ending soon, Suchon anticipates a significant market expansion, potentially benefiting millions more Canadians with type 2 diabetes and obesity. The company aims to manufacture the drug domestically in partnership with Applied Pharmaceutical Innovation.
Oct 17, 2025
Novo, Lilly, and Pfizer: Which Company Benefits If Trump Reduces Prices on Weight Loss Medications?
President Trump announced plans to reduce the price of Novo Nordisk's Ozempic from $1,300 to $150, potentially disrupting the GLP-1 market and impacting companies like Eli Lilly and Pfizer. Novo Nordisk's revenue could be affected, while lower prices may benefit competitors like Pfizer and Amgen. This pricing strategy could reshape the weight-loss drug landscape significantly.
Oct 17, 2025
Cardiol Therapeutics Obtains $11 Million in Funding, Extending Financial Resources Through Q3 2027
Cardiol Therapeutics Inc. has secured $11 million in funding to advance its Phase III MAVERIC trial of CardiolRx™ for recurrent pericarditis and to support the development of CRD-38, a next-generation heart failure therapy. New data from the ARCHER trial, showing significant reductions in left ventricular mass, will be presented at a cardiology conference in November 2025.
Oct 16, 2025
Production to Prescription Podcast: Upcoming Drug Releases and Approvals in 2025: The Next Big Hits...
In the latest episode of the Production to Prescription podcast, Matthew Arnold from Clarivate discusses potential blockbuster drug launches and approvals in 2025, highlighting key trends in mergers, acquisitions, and the impact of US trade policies on R&D. The podcast aims to keep the bio/pharmaceutical industry informed on significant developments affecting the market.
Oct 16, 2025
Mira Pharmaceuticals Shares Surge 70% in After-Hours Trading Following Pain Medication's Success Against Morphine - Stocktwits
Mira Pharmaceuticals' shares surged 70% after announcing preclinical data showing its oral drug candidate Mira-55 outperformed injected morphine in normalizing pain and reducing inflammation. The non-psychotropic marijuana analog demonstrated strong anti-inflammatory effects, supporting its upcoming Investigational New Drug application for chronic inflammatory pain. The stock has risen 16% in 2025, reflecting bullish investor sentiment.
Oct 16, 2025
How Will Sales of Mounjaro and Zepbound Contribute to Lilly's Q3 Performance? - TradingView
Eli Lilly (LLY) is thriving in the cardiometabolic market with its GLP-1 drugs, Mounjaro and Zepbound, which together account for over half of the company's revenue. Mounjaro leads T2D prescriptions with a 50% market share, while Zepbound commands 75% in obesity. Anticipated Q3 sales are $5.33 billion for Mounjaro and $3.46 billion for Zepbound.
Oct 16, 2025
Z2G Bio, a firm focused on creating effective and sustainable pharmaceuticals, has reintroduced t...
Z2G Bio has revived its Semaglutide patent, previously withdrawn, enhancing its competitive edge in the obesity treatment market. Semaglutide, a key ingredient in Novo Nordisk's "Wigobi" and Eli Lilly's "Munzaro," is crucial for diabetes and obesity therapies. The company aims to block competitors and expand globally, collaborating with Boehringer Ingelheim on long-term injection developments.
Oct 16, 2025
Amgen and Biocon Reach Settlement in Denosumab BPCIA Litigation - Patent - United States - Mondaq
On September 30, 2025, a U.S. District Court resolved the denosumab BPCIA litigation between Amgen, Inc. and Biocon Biologics, allowing Biocon's biosimilars, BOSAYA and AUKELSO, to launch on October 1, 2025. Biocon acknowledged the validity of 34 patents asserted by Amgen, which were linked to Amgen's PROLIA® and XGEVA®.
Oct 16, 2025
G2Z Bio, a local biotechnology company, has resubmitted several patents that it had previously withdrawn.
G2Z Bio has re-applied for patents related to Semaglutide, a key ingredient in obesity and diabetes treatments, after voluntarily withdrawing them earlier this year to avoid disputes. The company has successfully registered a split application for its long-term drug delivery technology, enhancing its patent portfolio and aiming to secure a competitive edge in the market.
Oct 16, 2025
Novartis unable to prevent the import of repackaged versions of its popular medication in Europe.
A judge ruled that it was unjustified for a pharma giant to maintain indefinite exclusivity over a $7.8 billion drug, signaling a potential significant revenue impact for the company.
Oct 16, 2025
Legal dispute in India challenges Roche's dominance in the rare disease sector - SWI swissinfo.ch
The Delhi High Court has allowed Indian generic manufacturer Natco to produce a low-cost version of Roche's spinal muscular atrophy drug, Evrysdi (risdiplam), potentially improving access for patients. Evrysdi costs ₹7 million annually in India, while Natco's generic, Natsmart, is priced at ₹15,900 per bottle. Roche plans to appeal the decision, which challenges its patent rights.
Oct 16, 2025
Investors are wagering that the profits of contract manufacturers will increase due to weight-loss medications - Mint
The surge in demand for weight-loss drugs like semaglutide and liraglutide is boosting Indian contract manufacturers, with companies like OneSource Specialty Pharma, Divi’s Laboratories, and Gland Pharma seeing share increases of up to 141%. Major Indian firms, including Sun Pharma and Dr Reddy’s, are preparing to launch generics as patents expire, anticipating a $5-10 billion market opportunity.
Oct 16, 2025
Vimy Pharma intends to produce a Canadian-made generic version of Ozempic.
Vimy Pharmaceuticals Inc., co-founded by former Novo Nordisk executives Dave Suchon and Farris Smith, aims to produce a Canadian generic version of semaglutide, the active ingredient in Ozempic, by 2026. With a focus on domestic production, Vimy Pharma plans to address the growing demand for diabetes and weight loss treatments while donating a portion of profits to Wounded Warriors Canada.
Oct 16, 2025
Mira Pharmaceuticals Shares Surge 70% in After-Hours Trading Following Superior Performance of Pain Medication Compared to Morphine
Mira Pharmaceuticals' shares surged 70% after announcing preclinical data showing its oral drug candidate, Mira-55, outperformed injected morphine in normalizing pain and reducing inflammation. The study highlighted Mira-55's dual action and potential for an Investigational New Drug application, positioning it strongly in the $70 billion non-opioid pain market. Retail sentiment on Stocktwits remains extremely bullish.
Oct 16, 2025
Upcoming Drug Releases and Approvals in 2025: Potential Blockbuster Candidates
In 2025, several bio/pharmaceuticals launched or approved are poised to become potential blockbusters, with sales exceeding $1 billion. Insights from Matthew Arnold of Clarivate highlight key trends and upcoming launches in the industry. The Production to Prescription podcast discusses various topics, including CDMO impacts and the biotech sector's outlook, featuring experts from L.E.K. Consulting and Ernst & Young.
Oct 15, 2025
Novel Benzoyl Sesquiterpenoid Compound Discovered in Mutant Strain KTF-0021 of Talaromyces
Researchers have discovered a new benzoyl sesquiterpenoid compound in the mutant fungal strain *Talaromyces* sp. KTF-0021, derived from FKI-5759. This breakthrough, achieved by activating silent biosynthetic gene clusters, emphasizes the potential of fungi in producing novel bioactive compounds for various applications.
Oct 15, 2025
Delhi High Court instructs firms to submit a chart containing information on prohibited FDCs.
The Delhi High Court has directed pharmaceutical companies to submit a chart detailing the banned fixed dose combinations (FDCs) and related petitions filed in court. This order aims to clarify the status of these drugs amid ongoing legal proceedings.
Oct 15, 2025
Novo Nordisk Secures New Complement System Strategy for Rare Diseases Through Agreement for Omeros Medication
Novo Nordisk has acquired global rights to Omeros' Phase 3-ready drug zaltenibart for $240 million, aiming to compete with existing immune disorder treatments from AstraZeneca, Novartis, and Apellis Pharmaceuticals. Zaltenibart targets MASP-3 to treat paroxysmal nocturnal hemoglobinuria (PNH) and other rare diseases. The deal supports Omeros' pipeline while Novo Nordisk plans a global Phase 3 program for the drug.
Oct 15, 2025
Yuhan Corporation's recently launched lung cancer medication "Leklaza" is expanding its market share within Johnson & Johnson.
Yuhan Corporation's lung cancer drug "Leklaza" is gaining traction in Johnson & Johnson's (J&J) global portfolio, with combined sales of Leklaza and "Libryvant" reaching $198 million in Q3, a 122% increase year-on-year. J&J anticipates annual sales could reach KRW 7 trillion. The combination therapy is expanding in non-small cell lung cancer markets, with FDA approval expected soon.
Oct 15, 2025
U.S. Postpones Tariffs on Pharmaceutical Exports from Singapore During Ongoing Trade Talks
The US has postponed the enforcement of a proposed 100% tariff on Singapore's pharmaceutical exports, originally set for October 1, 2025. This delay allows for negotiations between the US government and pharma companies, including Pfizer, which is working to lower drug prices and expand US manufacturing. Singapore exports approximately $3.1 billion in pharma products to the US annually.
Oct 15, 2025
Report on the Expansion of the Generic Drug Sector in Latin America from 2025 to 2033 - openPR.com
The Latin America generic drug market is projected to grow from USD 37.2 billion in 2024 to USD 64.2 billion by 2033, with a CAGR of 5.94%. Key drivers include rising demand for affordable healthcare, government support for generics, and increasing chronic disease prevalence. Notable developments include Brazil's ANVISA approving new generics and Teva Pharmaceuticals expanding manufacturing in Mexico.
Oct 14, 2025
Roche aims to stop Natco from selling its SMA medication - NewsBytes
The High Court ruled that Roche's patent was not sufficiently novel, allowing Natco to introduce its generic drug at ₹15,900 per bottle, significantly lower than Roche's ₹6 lakh price. This case highlights the ongoing debate in India regarding the balance between medicine patents and public health needs, with the Supreme Court hearing arguments this week.
Oct 14, 2025
Hatch-Waxman legal battles: The role of legal financing in aiding both brand-name and generic companies despite challenges...
Pharmaceutical companies are increasingly utilizing legal finance, particularly in Hatch-Waxman litigation, to optimize outcomes in patent disputes. Burford's funding allows both branded and generic drug manufacturers to manage litigation costs and pursue strategic opportunities, enhancing revenue potential. This approach supports innovation while balancing market exclusivity and affordability, ultimately providing companies with greater operational flexibility.
Oct 14, 2025
Financial challenges and ethical considerations: the cost, patents, and accessibility of lenacapavir.
Lenacapavir, branded as Yeztugo, has gained approval as the first twice-yearly HIV prevention shot. However, concerns arise over its potential price of $25,000 annually, despite production costs as low as $25. The manufacturer has initiated voluntary licensing with six generic companies for 120 countries, but exclusions and strict controls may hinder access. The global health community urges for significant price reductions to ensure equitable access.
Oct 14, 2025
Affordable Innovation: The Global Market for Generic Medications Set for Major Changes...
The Global Generic Drugs Market is projected to grow from USD 487.21 billion in 2024 to USD 898 billion by 2035, driven by patent expirations, rising healthcare costs, and chronic disease prevalence. Key players include Mylan N.V., Teva Pharmaceutical Industries, and Pfizer Inc. Challenges include price erosion and regulatory hurdles, while opportunities lie in biosimilars and emerging markets.
Oct 14, 2025
Daiichi Sankyo (TSE:4568): Insights on Valuation After Significant Progress in Oncology
Daiichi Sankyo Company is gaining attention with updates on its oncology pipeline, including late-breaking data for ENHERTU and other DXd antibody drug conjugates at the ESMO congress. Despite a 20.3% decline in 1-year shareholder return, a recent 9.5% rise suggests renewed investor optimism. The company's fair value is estimated at ¥5,529, indicating it may be undervalued.
Oct 14, 2025
Chinese Pharmaceutical Candidates Secure International Licensing Opportunities in Light of 2025 Patent Expiration Concerns
The global pharmaceutical industry is witnessing a surge in licensing agreements for drug candidates from China, driven by the impending 2025 patent cliff. This trend underscores China's growing influence and innovation in the sector, as multinational companies seek partnerships to mitigate revenue losses from expiring patents on blockbuster drugs.
Oct 14, 2025
Bristol-Myers Squibb (BMY): Robust Growth Prospects Backing Generous Dividend Yield
Bristol-Myers Squibb Company (NYSE:BMY) has been recognized as one of the 12 Best Dividend Stocks, boasting a yield of 5.64%. The company, known for its strong growth pipeline in oncology and other areas, anticipates significant sales from its new schizophrenia treatment, Cobenfy, projected to generate $2.6 billion by 2030. BMY has increased dividends for 16 consecutive years.
Oct 14, 2025
Kailera Raises $600 Million to Propel Dual-Targeting Obesity Medication into Global Phase 3 Trials
Kailera Therapeutics has secured $600 million for Phase 3 trials of its lead obesity drug candidate, KAI-9531, which targets GLP-1 and GIP receptors, similar to Eli Lilly's Zepbound. Preliminary results show a 19.2% weight loss in patients. The funding will also support other programs, including KAI-7535 and KAI-4729, as the company aims to address obesity treatment needs.
Oct 14, 2025
Roche Takes Legal Action in Supreme Court Following Delhi High Court Ruling Permitting Natco To ... - The Law Advice
F. Hoffmann-La Roche AG has appealed to the Supreme Court of India against a Delhi High Court ruling allowing Natco Pharma Ltd. to produce a generic version of Risdiplam, a drug for Spinal Muscular Atrophy. Roche claims Natco's product infringes its patent, while Natco argues the patent is invalid. The Supreme Court is set to hear Roche's plea soon.
Oct 14, 2025
Madhya Pradesh Requires Child Safety Labels on Cough and Cold Medications, Strengthens Regulations...
Madhya Pradesh has mandated child safety warnings on cough and cold medicines, specifically those containing chlorpheniramine maleate and phenylephrine HCl. The state is also tightening drug inspection protocols to enhance pediatric safety and strengthen pharmaceutical oversight.
Oct 13, 2025
Innovative Sterility Testing Technique Shortens Biopharmaceutical Quality Control Process to Just One Day
A new sterility testing method for biopharmaceuticals has reduced the quality control process to just one day, significantly improving upon traditional methods that take much longer. This advancement aims to enhance safety and efficiency in the production of biopharmaceuticals, which rely on biological components. The method maintains stringent safety standards while expediting product release timelines.
Oct 13, 2025
Securing Legal Protection for Biotech Innovations: An Overview of Patents in Biotechnology - BioTecNika
Biotechnology patents are essential for protecting innovations in medicine, agriculture, and environmental science, ensuring inventors can recover investments. Key patentable areas include genetically modified organisms, biological materials, and therapeutic products like mRNA vaccines from Pfizer/BioNTech and Moderna. However, challenges such as ethical concerns, patent trolls, and high costs complicate the landscape, necessitating a balance between protection and public access.
Oct 13, 2025
AstraZeneca commits to reducing drug prices in the US following Trump's influence - City AM
AstraZeneca has announced plans to reduce US medicine prices by up to 80% following pressure from President Donald Trump. The company will offer direct-to-consumer sales for chronic disease medications and participate in a new government purchasing platform. This strategy aims to avoid potential tariffs and reflects AstraZeneca's shift towards the US market, including a $50 billion investment in manufacturing and R&D.
Oct 13, 2025
Taiwan prepares for expansion in the global biopharmaceutical market as patents for billion-dollar medications come to an end.
Taiwan's pharmaceutical industry is gearing up for global competitiveness as nearly 50 brand-name drugs lose patent protection by 2034, creating opportunities for generics and biosimilars. EirGenix's breast cancer biosimilar EG1206A has gained FDA and EMA approval to skip Phase 3 trials. Other companies like Tanvex BioPharma and GlycoNex are also advancing in the biosimilar market.
Oct 13, 2025
Revolutionizing the pharmaceutical industry through autonomous AI - MIT Technology Review
The pharmaceutical industry faces significant challenges, including rising raw material costs, supply chain disruptions, and pressure to control drug prices, particularly in the US. With $300 billion in sales at risk from expiring patents by 2030, companies are also grappling with increasing drug launch costs, now averaging $4 billion. Demand for personalized and precision drugs is rising, complicating production and limiting market reach.
Oct 13, 2025
U.S. Market for Antiviral Medications Expected to Hit USD 23.61 Billion by 2030
The U.S. antiviral drugs market is projected to decline from USD 26.41 billion in 2024 to USD 23.61 billion by 2030, driven by reduced COVID-19 demand and increased generic adoption. HIV treatments dominate, accounting for 37.7% of revenue, while companies like Teva and Mylan expand affordable options. FDA approvals, including Mavyret for pediatric hepatitis C, highlight ongoing innovation.
Oct 13, 2025
Evaluation of additional charges for name-brand medications - Taipei Times
Taiwan's Health Minister Shih Chung-liang emphasized the need for careful evaluation of proposals allowing extra fees for imported brand-name drugs, as it may harm the perception of domestic generics. The FDA reported 47 drugs, mainly for hypertension and high cholesterol, are set to be discontinued, but substitutes are available. Concerns over food safety inspections were also raised during the meeting.
Oct 13, 2025
New Special Enforcement Unit to Be Established Following Cough Syrup Controversy, Reports DrugsControl Media Services
Madhya Pradesh is launching a Special Enforcement Cell to combat the rising issue of fake drugs, following public outrage over contaminated cough syrups. This initiative aims to enhance drug safety and ensure the integrity of pharmaceutical products in the state.
Oct 13, 2025
Moderna shares melanoma findings that influenced its choice to partner with IDO - Fierce Biotech
Moderna has reported promising phase 1/2 data for its cancer candidate mRNA-4359, showing a 24% objective response rate in melanoma patients previously treated with checkpoint inhibitors, including Merck & Co.'s Keytruda. The study suggests PD-L1 as a potential biomarker, with a 60% disease control rate. Moderna aims to leverage mRNA-4359's dual mechanism to enhance immune responses in difficult-to-treat patients.
Oct 13, 2025
Amgen Shareholders Anticipate Key FDA Decision on Major Drug Expansion
Amgen is under scrutiny as it awaits an FDA ruling on October 19 for its drug Tezspire, which seeks expanded approval for treating chronic sinusitis with nasal polyps. Positive clinical data shows significant efficacy, including a 98% reduction in surgical interventions. Approval could open access to a multibillion-dollar market, marking Tezspire's second major indication after severe asthma.
Oct 12, 2025
Pfizer (NYSE:PFE) stock continues to drop after the pandemic. What does the future hold for the company?
Pfizer's shares have dropped 12% in 2025 as the company faces declining revenues post-pandemic, with projections of US$54bn by 2029. Key drugs like Comirnaty and Paxlovid are seeing reduced demand, and several products are approaching patent expiration, risking US$17-18bn in revenues. Pfizer is acquiring companies like Seagen to mitigate losses but remains under pressure compared to more diversified firms like Johnson & Johnson.
Oct 12, 2025
Daiichi Sankyo (TSE:4568) Sees 9.0% Increase Following Significant Successes in Breast Cancer Research
AstraZeneca and Daiichi Sankyo announced that DATROWAY® (datopotamab deruxtecan-dlnk) significantly improved survival rates in first-line metastatic triple-negative breast cancer patients. Additionally, the FDA accepted a supplemental Biologics License Application for ENHERTU® as a neoadjuvant therapy in HER2-positive breast cancer, highlighting Daiichi Sankyo's growing influence in oncology and its innovative antibody-drug conjugate portfolio.
